NBY - NovaBay Pharmaceuticals, Inc.
1.48
0.050 3.378%
Share volume: 261,107
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$1.43
0.05
0.04%
View ratios
| Fiscal Date | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 11-07-2024 | 05-15-2025 | 08-14-2025 | 11-07-2025 | |
| Total revenue | 2.441 M | 0.000 | 0.000 | 521.000 K | |
| Cost of revenue | 848.000 K | 0.000 | 0.000 | 479.000 K | |
| Gross profit | 1.593 M | 0.000 | 0.000 | 42.000 K | |
| -100.00% | nan% | inf% | |||
| Operating expenses | 1.707 M | 2.701 M | 1.891 M | 1.211 M | |
| Selling general and admin | 1.703 M | 2.701 M | 1.891 M | 1.211 M | |
| Research and development | 4.000 K | 0.000 | 0.000 | 0.000 | |
| Total expenses | 2.654 M | 3.290 M | 1.891 M | 1.298 M | |
| 23.96% | -42.52% | -31.36% | |||
| Operating income | -1.061 M | -3.290 M | -1.891 M | -1.256 M | |
| Ebit | -1.061 M | -3.330 M | -1.964 M | -1.333 M | |
| Pretax income | -1.212 M | -3.330 M | -1.964 M | -1.333 M | |
| 174.75% | -41.02% | -32.13% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -1.212 M | 7.670 M | -1.922 M | -1.293 M | |
| 732.84% | -125.06% | 32.73% |